European Cooperative Trial in Operable Breast Cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF).

被引：0
|
作者：
Gianni, L
Baselga, J
Eiermann, W
Porta, VG
Semiglazov, V
Lluch, A
Zambetti, M
Valagussa, P
Bonadonna, G
机构：
[1] Ist Nazl Tumori, I-20133 Milan, Italy
[2] Hosp Gen Valle Hebron, Barcelona, Spain
[3] Red Cross Hosp, Munich, Germany
[4] Inst Valenciano Oncol, Valencia, Spain
[5] NN Petrov Oncol Res Inst, St Petersburg, Russia
[6] Univ Valencia, Hosp Clin, Valencia, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：7S / 7S
页数：1
相关论文
共 50 条
  • [1] Freedom from progression (FFP) by adding paclitaxel (T) to doxorubicin (A) followed by CMF as adjuvant or primary systemic therapy: 10-yr results of a randomized phase III European Cooperative Trial in Operable Breast Cancer (ECTO)
    Zambetti, Milvia
    Baselga, Jose
    Eiermann, Wolfgang
    Guillem, Vicente
    Semiglazov, Vladimir
    Lluch, Ana
    Sabadell, Dolores
    Bozhok, Alla
    Byakhov, Mikhail J.
    Ojeda, Belen
    Mansutti, Mauro
    Mariani, Gabriella
    Molitemi, Angela
    Cortes-Funes, Hernan
    Colozza, Marian
    Pienkowski, Tadeusz
    Magazzu, Domenico
    Valagussa, Pinuccia
    Bonadonna, Gianni
    Gianni, Luca
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer
    Gianni, Luca
    Baselga, Jose
    Eiermann, Wolfgang
    Porta, Vincente Guillem
    Semiglazov, Vladimir
    Lluch, Ana
    Zambetti, Milvia
    Sabadell, Dolores
    Raab, Guenther
    Cussac, Antonio Llombart
    Bozhok, Alla
    Martinez-Agullo, Angel
    Greco, Marco
    Byakhov, Mikhail
    Lopez, Juan Jose Lopez
    Mansutti, Mauro
    Valagussa, Pinuccia
    Bonadonna, Gianni
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15) : 2474 - 2481
  • [3] Sequential administration of doxorubicin and paclitaxel followed by cyclophosphamide, methotrexate and 5-fluorouracil combination (CMF) in women with metastatic breast cancer
    Papadimitriou, CA
    Dimopoulos, MA
    Ampela, C
    Louvrou-Fertaki, A
    Anagnostopoulos, A
    Athanassiades, P
    Stamatelopoulos, S
    Keramopoulos, A
    ONCOLOGY, 1998, 55 (06) : 533 - 537
  • [4] EPIRUBICIN (E) FOLLOWED BY CYCLOPHOSPHAMIDE, METHOTREXATE AND 5-FLUOROURACIL (CMF) VERSUS PACLITAXEL (T) FOLLOWED BY EPIRUBICIN AND VINORELBINE (EV) IN PATIENTS WITH HIGH-RISK OPERABLE BREAST CANCER
    Guglielmini, Pamela
    Sismondi, Piero
    Farris, Antonio
    Amadori, Dino
    Agostara, Biagio
    Gambi, Angelo
    Catalano, Giuseppina
    Faedi, Marina
    Rubagotti, Alessandra
    Boccardo, Francesco
    ANNALS OF ONCOLOGY, 2009, 20
  • [5] Epirubicin (E) followed by cyclophosphamide, methotrexate, 5-fluorouracil (CMF) versus paclitaxel (T) followed by epirubicin and vinorelbine (EV) in patients (pts) with high-risk operable breast cancer
    Boccardo, F.
    Rubagotti, A.
    Guglielmini, P.
    Sismondi, P.
    Farris, A.
    Amadori, D.
    Agostara, B.
    Gambi, A.
    Catalano, G.
    Faedi, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] CLINICAL CONTROLLED TRIAL IN ADVANCED BREAST-CANCER - CMF (CYCLOPHOSPHAMIDE, METHOTREXATE, 5-FLUOROURACIL) VERSUS CMF+T (CYCLOPHOSPHAMIDE, METHOTREXATE, 5-FLUOROURACIL, TAMOXIFEN)
    HINDY, I
    NEOPLASMA, 1985, 32 (03) : 381 - 387
  • [7] Lessons from the initial adjuvant cyclophosphamide, methotrexate, and fluorouracil studies in operable breast cancer
    Bonadonna, Gianni
    Valagussa, Pinuccia
    Veronesi, Umberto
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (03) : 342 - 344
  • [8] Epirubicin Followed by Cyclophosphamide, Methotrexate and 5-Fluorouracil versus Paclitaxel Followed by Epirubicin and Vinorelbine in Patients with High-Risk Operable Breast Cancer
    Boccardo, Francesco
    Amadori, Dino
    Guglielmini, Pamela
    Sismondi, Piero
    Farris, Antonio
    Agostara, Biagio
    Gambi, Angelo
    Catalano, Giuseppina
    Faedi, Marina
    Rubagotti, Alessandra
    ONCOLOGY, 2010, 78 (3-4) : 274 - 281
  • [9] Prospective randomized trial of paclitaxel alone versus 5-fluorouracil/doxorubicin/cyclophosphamide as induction therapy in patients with operable breast cancer
    Buzdar, AU
    Hortobagyi, GN
    Asmar, L
    Theriault, RL
    Rahman, Z
    McNeese, M
    Singletary, S
    Ames, F
    SEMINARS IN ONCOLOGY, 1997, 24 (05) : 31 - 34
  • [10] The comparative study of adjuvant chemotherapy of breast cancer with cyclophosphamide, methotrexate, 5-fluorouracil (CMF) versus doxorubicin, cyclophosphamide (AC). First results of national cooperative study
    Pribylova, O
    Petruzelka, L
    Fischer, J
    Bustova, I
    Siffnerova, H
    Kuta, M
    Muller, V
    Hacklova, M
    Machacek, J
    Kohoutek, M
    Vodvarka, P
    Kysela, T
    Tajblova, J
    17TH INTERNATIONAL CANCER CONGRESS, VOL 1 AND 2, 1998, : 811 - 815
12345